The role of pancreatic imaging in monogenic diabetes mellitus

Nature Reviews Endocrinology

Volumn 8, Issue 3, 2012, Pages 148-159

  Haldorsen, Ingfrid S ^a   Ræder, Helge ^a   Vesterhus, Mette ^a   Molven, Anders ^b   Njølstad, Pål R ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CALCINOSIS; DIABETES MELLITUS; DIAGNOSTIC IMAGING; GENETICS; HUMAN; LIPOMATOSIS; METHODOLOGY; MUTATION; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PATHOLOGY; REVIEW;

ANIMALS; CALCINOSIS; DIABETES MELLITUS; DIAGNOSTIC IMAGING; HUMANS; INSULIN-SECRETING CELLS; LIPOMATOSIS; MUTATION; PANCREATIC DISEASES;

EID: 84865135270     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.197     Document Type: Article

References (125)

1. Hattersley, A., Bruining, J., Shield, J., Njdlstad, P. & Donaghue, K. C. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes 10 Suppl. 12, 33-42 (2009).
2. Molven, A. & Njdlstad, P. R. Role of molecular genetics in transforming diagnosis of diabetes mellitus. Expert Rev. MoL Diagn. 11, 313-320 (2011).
3. Fajans, S. S. & Bell, G. I., MODY: History, genetics, pathophysiology, and clinical decision making. Diabetes Care 34, 1878-1884 (2011).
4. Flechtner, I. et al. Neonatal hyperglycaemia and abnormal development of the pancreas. Best Pract. Res. Clin. Endocrinol. Metab. 22, 17-0 (2008).
5. Eide, S. A. et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 study). Diabet. Med. 25, 775-781 (2008).
6. Shields, B. M. et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53, 2504-2508 (2010).
7. Kropff, J., Selwood, M. P., McCarthy, M. I., Farmer, A. J. & Owen, K. R. Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia 54, 1261-1263 (2011).
8. Murphy, R., Ellard, S. & Hattersley, A. T. Clinical implications of a molecular genetic classification of monogenic (3-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4, 200-213 (2008)).
9. Haldorsen, I. S. et al. Lack of pancreatic body and tail in HNF1B mutation carriers. Diabet. Med. 25, 782-787 (2008).
10. Sellick, G. S. et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat. Genet. 36, 1301-1305 (2004).
11. Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L. & Habener, J. F. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. 15, 106-110 (1997).
12. R-der, H. et al. Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes 56, 444-449 (2007).
13. R-der, H. et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. 38, 54-62 (2006).
14. Kinney, T. P. & Freeman, M. L., Recent advances and novel methods in pancreatic imaging. Minerva Gastroenterol. Dietol. 54, 85-95 (2008).
15. Nijs, E., Callahan, M. J. & Taylor, G. A., Disorders of the pediatric pancreas: imaging features. Pediatr. Radiol. 35, 358-373 (2005).
16. Wallace, M. B. Imaging the pancreas: into the deep. Gastroenterology 132, 484-87 (2007).
17. Saisho, Y. et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin. Anat. 20, 933-942 (2007).
18. Stamm, B. H. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum. Pathol. 15, 677-683 (1984).
19. Lohr, M. & Kloppel, G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30, 757-762 (1987).
20. Goda, K. et al. Pancreatic volume in type 1 and type 2 diabetes mellitus. Acta Diabetol. 38, 145-149 (2001).
21. Altobelli, E. et al. Size of pancreas in children and adolescents with type I (insulin-dependent) diabetes. J. Clin. Ultrasound 26, 391-395 (1998).
22. Alzaid, A., Aideyan, O. & Nawaz, S. The size of the pancreas in diabetes mellitus. Diabet. Med. 10, 759-763 (1993).
23. Williams, A. J., Chau, W., Callaway, M. P. & Dayan, C. M. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in type 1 diabetes. Diabet. Med. 24, 35-0 (2007).
24. Gaglia, J. L. et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. Invest. 121, 442-445 (2011).
25. Vesterhus, M., Haldorsen, I. S., Raeder, H., Molven, A. & Njdlstad, P. R. Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity- onset diabetes of the young. J. Clin. Endocrinol. Metab. 93, 3505-3509 (2008).
26. Gilbeau, J. P., Poncelet, V., Libon, E., Derue, G. & Heller, F. R. The density, contour, and thickness of the pancreas in diabetics: CT findings in 57 patients. AJR Am. J. Roentgenol. 159, 527-531 (1992).
27. Nakamura, Y, Higuchi, S. & Maruyama, K. Pancreatic volume associated with endocrine and exocrine function of the pancreas among Japanese alcoholics. Pancreatology 5, 422-431 (2005).
28. Bilgin, M. et al. MRI and MRCP findings of the pancreas in patients with diabetes mellitus: compared analysis with pancreatic exocrine function determined by fecal elastase 1. J. Clin. Gastroenterol. 43, 165-170 (2009).
29. Sunnapwar, A. et al. Nonalcoholic, nonbiliary pancreatitis: cross-sectional imaging spectrum. AJR Am. J. Roentgenol. 195, 67-75 (2010).
30. Kim, D. H. & Pickhardt, P. J., Radiologic assessment of acute and chronic pancreatitis. Surg. Clin. North Am. 87, 1341-1358 (2007).
31. Kovanlikaya, A. et al. Obesity and fat quantification in lean tissues using three-point Dixon MR imaging. Pediatr. Radiol. 35, 601-607 (2005).
32. Tushuizen, M. E. et al. Pancreatic fat content and (3-cell function in men with and without type 2 diabetes. Diabetes Care 30, 2916-2921 (2007)).
33. Smits, M. M. & van Geenen, E. J. The clinical significance of pancreatic steatosis. Nat. Rev. Gastroenterol. Hepatol. 8, 169-177 (2011).
34. Lesniak, R. J., Hohenwalter, M. D. & Taylor, A. J. Spectrum of causes of pancreatic calcifications. AJR Am. J. Roentgenol. 178, 79-86 (2002).
35. Ikeda, M. et al. Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. Pancreas 9, 508-512 (1994).
36. Glaser, J. & Stienecker, K. Pancreas and aging: a study using ultrasonography. Gerontology 46, 93-96 (2000).
37. Ellard, S., Bellanne-Chantelot, C. & Hattersley, A. T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51, 546-553 (2008).
38. Bingham, C. et al. The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1a mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 50, 2047-2052 (2001).
39. Osbak, K. K. et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum. Mutat. 30, 1512-1526 (2009).
40. Conn, J. J. et al. Neonatal hyperinsulinaemic hypoglycaemia and monogenic diabetes due to a heterozygous mutation of the HNF4A gene. Aust. NZ J. Obstet. Gynaecol. 49, 328-330 (2009).
41. Pearson, E. R., Recent advances in the genetics of diabetes. Prim. Care Diabetes 2, 67-72 (2008).
42. Edghill, E. L. et al. Hepatocyte nuclear factor-1p mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1B in human pancreatic development. Diabet. Med. 23, 1301-1306 (2006).
43. Bellanné-Chantelot, C. et al. Clinical spectrum associated with hepatocyte nuclear factor-1p mutations. Ann. intern. Med. 140, 510-517 (2004).
44. Yorifuji, T. et al. Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys; phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1p gene due to germline mosaicism. J. Clin. Endocrinol. Metab. 89, 2905-2908 (2004).
45. Gonc, E. N. et al. HNFIB mutation in a Turkish child with renal and exocrine pancreas insufficiency, diabetes and liver disease. Pediatr. Diabetes.
46. Zuber, J. et al. HNF1B-related diabetes triggered by renal transplantation. Nat. Rev. Nephrol. 5, 480-84 (2009).
47. Haumaitre, C. et al. Lack of Tcf2/vHnf1 in mice leads to pancreas agenesis. Proc. Natl Acad. Sci. USA 102, 1490-1495 (2005).
48. Bonner-Weir, S., et al.B-cell growth and regeneration; replication is only part of the story. Diabetes 59, 2340-2348 (2010).
49. Kovanlikaya, A., Guclu, C., Desai, C., Becerra, R. & Gilsanz, V Fat quantification using three-point Dixon technique; in vitro validation. Acad. Radiol. 12, 636-639 (2005).
50. Stoffers, D. A., Ferrer, J., Clarke, W. L. & Habener, J. F. Early-onset type-ll diabetes mellitus (M0DY4) linked to IPF1. Nat. Genet. 17, 138-139 (1997).
51. Gonsorcikova, L. et al. Autosomal inheritance of diabetes in two families characterized by obesity and a novel H241Q mutation in NEUR0D1. Pediatr. Diabetes 9, 367-372 (2008).
52. Fernandez-Zapico, M. E. et al. MODY7 gene, KLF11, is a novel p300-dependent regulator of Pdx-1 (M0DY4) transcription in pancreatic islet B cells. J. Biol. Chem. 284, 36482-36490.
53. Plengvidhya, N. et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J. Clin. Endocrinol. Metab. 92, 2821-2826 (2007).
54. Shimajiri, Y. et al. A missense mutation of PAX4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes 50, 2864-2869 (2001).
55. Molven, A. et al. Mutations in the insulin gene can cause M0DY and autoantibody-negative type 1 diabetes. Diabetes 57, 1131-1135 (2008).
56. Borowiec, M. et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and (3-cell dysfunction. Proc. Natl Acad. Sci. USA 106, 14460-14465 (2009)).
57. von Muhlendahl, K. E. & Herkenhoff, H. Longterm course of neonatal diabetes. N. Engl. J. Med. 333, 704-708 (1995).
58. Shield, J. P. et al. Aetiopathology and genetic basis of neonatal diabetes. Arch. Dis. Child. Fetal Neonatal Ed. 76, 39-42 (1997).
59. Edghill, E. L. et al. Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J. Clin. Endocrinol. Metab. 92, 1773-1777 (2007).
60. Greeley, S. A. et al. Update in neonatal diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 13-19.
61. Gloyn, A. L. et al. Activating mutations in the gene encoding the ATP-sensitive potassium- channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
62. Slingerland, A. S. et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260, 000 live births. Oiabetologia 52, 1683-1685 (2009).
63. Bappal, B., Raghupathy, P, de, S. V., & Khusaiby, S. M., Permanent neonatal diabetes mellitus; clinical presentation and epidemiology in Oman. Arch. Dis. Child. Fetal Neonatal Fd. 80, F209-F212 (1999).
64. Stoy, J. et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl Acad. Sci. USA 104, 15040-15044 (2007).
65. Edghill, E. L. et al. Insulin mutation screening in 1, 044 patients with diabetes; mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 57, 1034-1042 (2008).
66. Polak, M. et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy; a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 57, 1115-1119 (2008).
67. Temple, I. K. & Shield, J. P Transient neonatal diabetes, a disorder of imprinting. J. Med. Genet. 39, 872-875 (2002).
68. Thomas, I. H. et al. Neonatal diabetes mellitus with pancreatic agenesis in an infant with homozygous IPF-1 Pro63fsX60 mutation. Pediatr. Diabetes 10, 492-496 (2009).
69. Schwitzgebel, V. M. et al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J. Clin. Endocrinol. Metab. 88, 4398-406 (2003).
70. Nicolino, M. et al. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes 59, 733-740 (2010).
71. Rubio-Cabezas, O. et al. Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J. Clin. Endocrinol. Metab. 94, 4162-170 (2009).
72. Wildin, R. S., Smyk-Pearson, S. & Filipovich, A. H., Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39, 537-545 (2002).
73. Smith, S. B. et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 463, 775-780 (2010).
74. Mitchell, J. et al. Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia; search for the aetiology of a new autosomal recessive syndrome. Diabetologia 47, 2160-2167 (2004).
75. Dimitri, P. et al. Novel GLIS3 mutations demonstrate an extended multisystem phenotype. Fur. J. Endocrinol. 164, 437-43 (2011).
76. Senée, V. et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat. Genet. 38, 682-687 (2006).
77. Williams, J. A. & Goldfine, I. D. The insulin- pancreatic acinar axis. Diabetes 34, 980-986 (1985).
78. Henderson, J. R. Why are the islets of Langerhans? Lancet 2, 469-70 (1969).
79. Johansson, B. B. et al. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase gene (CEL-MODY); a protein misfolding disease. J. Biol. Chem. 286, 34593-34605 (2011).
80. Heni, M. et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance; a nuclear magnetic resonance study. Diabetes Metab. Res. Rev. 26, 200-205 (2010).
81. Nagashima, K., Yagi, H. & Kuroume, T. A case of Johanson-Blizzard syndrome complicated by diabetes mellitus. Clin. Genet. 43, 98-100 (1993).
82. Burroughs, L., Woolfrey, A. & Shimamura, A., Shwachman-Diamond syndrome; a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol. Oncol. Clin. North Am. 23, 233-248 (2009).
83. Stecenko, A. A. & Moran, A. Update on cystic fibrosis-related diabetes. Curr. Opin. Pulm. Med. 16, 611-615 (2010).
84. James, C., Kapoor, R. R., Ismail, D. & Hussain, K. The genetic basis of congenital hyperinsulinism. J. Med. Genet. 46, 289-299 (2009).
85. Palladino, A. A. & Stanley, C. A., A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism. Semin. Pediatr. Surg. 20, 32-37.
86. Marquard, J., Palladino, A. A., Stanley, C. A., Mayatepek, E. & Meissner, T. Rare forms of congenital hyperinsulinism. Semin. Pediatr. Surg. 20, 38-44 (2011).
87. Sandal, T. et al. The spectrum of ABCC8 mutations in Norwegian patients with congenital hyperinsulinism of infancy. Clin. Genet. 75, 440-448 (2009).
88. Otonkoski, T. et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with 18F-D0PA positron emission tomography. Diabetes 55, 13-18 (2006).
89. Ismail, D. & Hussain, K. Role of 18F-D0PA PET/CT imaging in congenital hyperinsulinism. Rev. Endocr. Metab. Disord. 11, 165-169 (2010).
90. Mohnike, K., et al. 18F-D0PA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm. Res. 70, 65-72 (2008).
91. Hardy, O. T. et al. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J. Pediatr. 150, 140-145 (2007).
92. Hardy, O. T. et al. Accuracy of 18F fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J. Clin. Endocrinol. Metab. 92, 4706-711 (2007).
93. Capito, C. et al. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 253, 216-222 (2009).
94. Masue, M. et al. Diagnostic accuracy of 18F fluoro-L-D0PA PET scan for persistent congenital hyperinsulinism in Japan. Clin. Endocrinol. (Oxf.) 75, 342-346 (2011).
95. Mohnike, W., Barthlen, W., Mohnike, K. & Blankenstein, O., Positron emission tomography/computed tomography diagnostics by means of fluorine-18-L-dihydroxyphenylalanine in congenital hyperinsulinism. Semin. Pediatr. Surg. 20, 23-27 (2011).
96. Zani, A. et al. The predictive value of preoperative fluorine-18-L-3, 4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J. Pediatr. Surg. 46, 204-208 (2011).
97. Otonkoski, T. et al. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 48, 408-415 (1999).
98. Nestorowicz, A. et al. Genetic heterogeneity in familial hyperinsulinism. Hum. Mol. Genet. 7, 1119-1128 (1998).
99. Verkarre, V. et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia, J. Clin. invest. 102, 1286-1291 (1998).
100. De Lonlay, P. et al. Congenital hyperinsulinism: pancreatic 18F-fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J. Clin. Endocrinol. Metab. 91, 933-940 (2006).
101. Villiger, M., Goulley, J., Martin-Williams, E. J., Grapin-Botton, A. & Lasser, T. Towards high resolution optical imaging of В cells in vivo. Curr. Pharm. Des. 16, 1595-1608 (2010).
102. Gotthardt, M., В cell imaging-why we need it and what has been achieved. Curr. Pharm. Des. 16, 1545-1546 (2010).
103. Ahlgren, U. & Gotthardt, M. Approaches for imaging islets: recent advances and future prospects. Adv. Exp. Med. Biol. 654, 39-57 (2010).
104. Leibiger, I. B., Caicedo, A. & Berggren, P. O., Non-invasive in vivo imaging of pancreatic B-cell function and survival-a perspective. Acta Physiol.
105. Brom, M., AndratoJc, K., Oyen, W. J., Boerman, O. C. & Gotthardt, M. Development of radiotracers for the determination of the B-cell mass in vivo. Curr. Pharm. Des. 16, 1561-1567 (2010).
106. Toso, C. et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am. J. Transplant. 8, 701-706 (2008).
107. Medarova, Z. & Moore, A. MRI as a tool to monitor islet transplantation. Nat. Rev. Endocrinol. 5, 444-452 (2009).
108. Antkowiak, P. F. et al. Noninvasive assessment of pancreatic B-cell function in vivo with manganese- enhanced magnetic resonance imaging. Am. J. Physiol. Endocrinol. Metab. 296, 573-578 (2009).
109. Barthlen, W. et al. Evaluation of 18F fluoro-L-DOPA positron emission tomography- computed tomography for surgery in focal congenital hyperinsulinism. J. Clin. Endocrinol. Metab. 93, 869-875 (2008).
110. Freeby, M. et al. VMAT2 quantitation by PET as a biomarker for B-cell mass in health and disease. Diabetes Obes. Metab. 10 Suppl. 4, 98-108 (2008).
111. Veluthakal, R. & Harris, P., in vivo B-cell imaging with VMAT 2 ligands-current state-of-the-art and future perspective. Curr. Pharm. Des. 16, 1568-1581 (2010).
112. Medarova, Z. & Moore, A. MRI in diabetes: first results. AJR Am. J. Roentgenol. 193, 295-303 (2009).
113. Hirshberg, B. et al. Pancreatic perfusion of healthy individuals and type 1 diabetic patients as assessed by magnetic resonance perfusion imaging. Diabetologia 52, 1561-1565 (2009).
114. Balci, N. C. et al. Diffusion-weighted magnetic resonance imaging of the pancreas. Top. Magn. Reson. Imaging 20, 43-47 (2009).
115. Hu, H. H., Kim, H. W., Nayak, K. S. & Goran, M. I. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity (SilverSpring) 18, 841-847 (2010).
116. Martínek, A., Klvana, P, Marten, P., Lesková, M. & Dvorácková, J. Are ultrasonic images in diabetics different? [Czech]. Vnitr. Lek. 47, 324-329 (2001).
117. Lindner, T. et al. Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4a/MODY1 gene. J. Clin. invest. 100, 1400-1405 (1997).
118. Thanabalasingham, G. et al. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54, 2801-2810 (2011).
119. McDonald, T. j. et al. High-sensitivity CRP discriminates HNF1A-M0DY from other sub-types of diabetes. Diabetes Care 34, 1860-1862 (2011).
120. Stoy, J. et al. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr. Diabetes 9, 450-459 (2008).
121. Babenko, A. P. et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456-66 (2006).
122. Garin, I. et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc. Natl Acad. Sci. USA 107, 3105-3110 (2010).
123. Russo, L. et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 54, 1693-1701 (2011).
124. Zalloua, P. A. et al. WFS1 mutations are frequent monogenic causes of Juvenile-onset diabetes mellitus in Lebanon. Hum. Mol. Genet. 17, 4012-021 (2008).
125. Rigoli, L., Lombardo, F. & Di, B. C., Wolfram syndrome and WFS1 gene. Clin. Genet. 79, 103-117 (2011).